Baxalta submits immunodeficiency drug to FDA; Alnylam advances a metabolic treatment;

@FierceBiotech: Patrick Soon-Shiong plucks another cancer drug out of Amgen's pipeline. Story | Follow @FierceBiotech

@JohnCFierce: Lipstick on a pig: XenoPort plunges as investors sour fast on "positive" psoriasis data. Article | Follow @JohnCFierce

@DamianFierce: Reminder that $NVO is risking billions of dollars on Tresiba data that management ~hasn't actually seen~. More from Reuters | Follow @DamianFierce

> Baxalta ($BXLT) submitted an FDA application for a new immunoglobulin therapy designed to treat primary immunodeficiencies. News

> Alnylam ($ALNY) is moving forward with an early-stage treatment for a rare metabolic disorder after charting positive signs in a Phase I study. More

> Genfit is developing a diagnostic test for nonalcoholic steatohepatitis (NASH). Item

Medical Device News

@FierceMedDev: Study: close management of blood pressure reduces cardiac disease, deaths. Article | Follow @FierceMedDev

@VarunSaxena2: UPDATED: FDA begs manufacturers to participate in global single audit pilot, says next stage may not be voluntary. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Advera Health Analytics: Merck statins linked to more muscle side effects than rest of class. Report | Follow @EmilyWFierce

> Olympus, Sony focus on JV with high-def endoscope launch. Report

> Med tech IPOs fall into place: Penumbra, Symetis, Novocure and Adesto. Story

> Philips, Salesforce develop diabetes app, system to marry consumer and medical data. Article

Pharma News

@FiercePharma: Regulatory challenges top of mind at inaugural ACI animal health forum. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. More | Follow @EricPFierce

@CarlyHFierce: ICYMI: Boehringer's Ofev, chasing a Roche rival, wins backing from NICE. Story | Follow @CarlyHFierce

> Payer hardball cuts price growth, with biggest hits in diabetes, COPD and hep C. Report

> Lilly gets preliminary NICE thumbs-down for Cyramza in stomach cancer. Story

> AbbVie edges closer to Imbruvica deal payoff with another FDA filing. Article

Drug Delivery News

> Novo, MIT's Langer Lab announce research alliance aimed at creating novel drug delivery devices. More

> Gene delivery player to go public this week, aiming to raise $100M. Item

> U.S.-Irish collaboration picks up $4.4M in pursuit of pancreatic cancer nanomeds. Report

> New surface protein found on cancer cells offers specific drug targeting, could spare fertility. Story

> Study finds ultrasound contrast agents can improve delivery of chemotherapy drugs. Article

Pharma Manufacturing News

> Abbott run-in with Indian regulators illustrates India's shortcomings: Reuters. More

> Endo's Qualitest recalls blood pressure, gout drugs. News

> California law requires drug info in 6 languages. Item

> U.K.'s Abzena shells out $8.4M for San Diego-based CDMO. Story

> FDA bans India's Polydrug plant, following actions by EMA and Canada. Article

Pharma Asia News

> China plans public health push on cancer, wants to expand screening. Report

> Japan's Eisai to present papers on Lenvima clinical data at European Cancer Congress. More

> Takeda crosses Actos settlement threshold as 96% of plaintiffs seek resolution. Story

> China plans medical exchange league with Arab states. Item

> Indian generics bid to challenge Gilead's Sovaldi patent dropped. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.